Literature DB >> 34272516

The dawning of dual-acting incretin drugs.

Shimona Starling1.   

Abstract

Year:  2021        PMID： 34272516     DOI： 10.1038/s41574-021-00540-y

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  2 in total

1.  Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.

Authors:  Julio Rosenstock; Carol Wysham; Juan P Frías; Shizuka Kaneko; Clare J Lee; Laura Fernández Landó; Huzhang Mao; Xuewei Cui; Chrisanthi A Karanikas; Vivian T Thieu
Journal:  Lancet       Date:  2021-06-27       Impact factor: 79.321

2.  Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

Authors:  Juan P Frías; Melanie J Davies; Julio Rosenstock; Federico C Pérez Manghi; Laura Fernández Landó; Brandon K Bergman; Bing Liu; Xuewei Cui; Katelyn Brown
Journal:  N Engl J Med       Date:  2021-06-25       Impact factor: 91.245
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.